Premium
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up
Author(s) -
GambacortiPasserini Carlo,
Brümmendorf Tim H.,
Kim DongWook,
Turkina Anna G.,
Masszi Tamas,
Assouline Sarit,
Durrant Simon,
Kantarjian Hagop M.,
Khoury H. Jean,
Zaritskey Andrey,
Shen ZhiXiang,
Jin Jie,
Vellenga Edo,
Pasquini Ricardo,
Mathews Vikram,
Cervantes Francisco,
Besson Nadine,
Turnbull Kathleen,
Leip Eric,
Kelly Virginia,
Cortes Jorge E.
Publication year - 2014
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23728
Subject(s) - bosutinib , medicine , imatinib , dasatinib , nilotinib , nausea , adverse effect , gastroenterology , myeloid leukemia , oncology , rash , tyrosine kinase inhibitor , cancer
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2‐year follow‐up of a phase 1/2 open‐label study evaluating the efficacy and safety of bosutinib as second‐line therapy in 288 patients with chronic phase CML resistant ( n = 200) or intolerant ( n = 88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2‐year estimates of retaining response >70%. Two‐year probabilities of progression‐free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib‐resistant and imatinib‐intolerant patients and did not differ with age. The longer‐term results of the present analysis confirm that bosutinib is an effective and tolerable second‐line therapy for patients with imatinib‐resistant or imatinib‐intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732–742, 2014. © 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.